BamSEC and AlphaSense Join Forces
Learn More

Aligos Therapeutics Inc. – Material Contracts

NASDAQ: ALGS    
Share price (6/23/26): $5.65    
Market cap (6/23/26): $35.0 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 4 pages Aligos Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.3
from 10-Q 9 pages Aligos Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.1
from 8-K 2 pages Amendment to Aligos Therapeutics, Inc. 2020 Incentive Award Plan
12/34/56
EX-10.1
from 10-Q 4 pages Aligos Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.20
from 10-K 5 pages Aligos Therapeutics, Inc. One Corporate Drive, 2ndfloor South San Francisco, California
12/34/56
EX-10.19
from 10-K 18 pages Registration Rights Agreement
12/34/56
EX-10.18
from 10-K 33 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 5 pages Aligos Therapeutics, Inc. One Corporate Drive, 2nd Floor South San Francisco, California
12/34/56
EX-10.3
from 8-K 17 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 54 pages Securities Purchase Agreement
12/34/56
EX-10.1(C)
from 10-Q 6 pages Aligos Therapeutics, Inc. 2024 Employment Inducement Award Plan Restricted Stock Unit Award Grant Notice
12/34/56
EX-10.1(B)
from 10-Q 9 pages Aligos Therapeutics, Inc. 2024 Employment Inducement Award Plan Stock Option Grant Notice
12/34/56
EX-10.1(A)
from 10-Q 21 pages Aligos Therapeutics, Inc. 2024 Employment Inducement Award Plan
12/34/56
EX-10.3
from 10-Q 4 pages Aligos Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.2
from 10-Q Pdf Courtesy Copy
12/34/56
EX-10.2
from 10-Q 5 pages Aligos Therapeutics, Inc. September 4, 2024
12/34/56
EX-10.1
from 10-Q 4 pages Aligos Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.1
from 8-K 2 pages Amendment to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan Effective June 27, 2024
12/34/56
EX-10.18
from 10-K 10 pages Separation and General Release Agreement
12/34/56